ClinicalTrials.gg

Program

sanritatug

Also written as “SG301 SC Injection”, “SG301 Injection” and “SG301”.

Its studies are mostly in Lupus Erythematosus, Systemic · Multiple Myeloma, led by Hangzhou Sumgen Biotech.

Furthest: phase 3, since Jul 5, 20245 company-led studies, 4 open or runningNext primary completion: Mar 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Sumgen Biotech54 open or runningphase 3since Jul 5, 2024Dec 10, 2020Mar 31, 2027phase 2 · NCT07764627

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 10, 2020First study: phase 1 study in RecurrenceFirst studyNCT04684108 · 61 enrolled · China
  2. Nov 13, 2023Phase 1 study in Lupus Erythematosus, SystemicNCT06144710 · 48 enrolled · China
  3. Jul 5, 2024Phase 3 study in Multiple MyelomaNCT06508983 · 360 planned · China
  4. Feb 25, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07447986 · 120 planned · China
  5. Aug 10, 2026Phase 2 study in Antibody Mediated RejectionNCT07764627 · 10 planned · China

Ahead

  1. Mar 31, 2027Primary completion: phase 2 study in Antibody Mediated RejectionNCT07764627
  2. Mar 31, 2027Primary completion: phase 3 study in Multiple MyelomaNCT06508983
  3. Sep 30, 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07447986

TargetBeta

CD38 →read by rule
“A human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that targets the cell surface glycoprotein CD38, ”NCIt, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07764627Antibody Mediated Rejection · China2Not yet recruitingMar 31, 202710
NCT07447986Lupus Erythematosus, Systemic · China2RecruitingSep 30, 2027120
NCT06508983Multiple Myeloma · China3RecruitingMar 31, 2027360
NCT06144710Lupus Erythematosus, Systemic · China1CompletedJan 7, 202648
NCT04684108Recurrence · China1Active, not recruitingJun 30, 202461

How it is read

Names in the registry

  • “SG301 SC Injection”, 3 entries
  • “SG301 Injection”, 2 entries
  • “SG301”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.